Firebrick Pharma Limited (ASX:FRE)

Market Cap	17.05M
Revenue (ttm)	524.69K
Net Income (ttm)	-2.63M
Shares Out	227.32M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,016
Average Volume	72,997
Open	0.0780
Previous Close	0.0750
Day's Range	0.0750 - 0.0800
52-Week Range	0.0510 - 0.1000
Beta	1.36
RSI	49.19
Earnings Date	Aug 29, 2025

About Firebrick Pharma

Firebrick Pharma Limited engages in the development and commercializing of novel formulations for the uses of povidone iodine in Australia. The company offers broad-spectrum antimicrobial nasal spray for the treatment of common cold under the Nasodine name. It also operates in the United states and Singapore. Firebrick Pharma Limited was incorporated in 2012 and is based in Melbourne, Australia.

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: FRE

Financial Performance

In 2025, Firebrick Pharma's revenue was 524,688, a decrease of -80.92% compared to the previous year's 2.75 million. Losses were -2.63 million, 124.0% more than in 2024.